Skip to content
Secure, Fast & Reliable Digital Solutions Need help choosing the right solution? Speak to our team
+254 775 115 430 info@reliancy.ai
Get Started
Technology News

RADICAL Trial: Radium-223 Plus Cabozantinib Does Not Improve SSE-FS in mRCC With Bone Metastases – Oncodaily

July 29, 2026 · 1 min read
RADICAL Trial: Radium-223 Plus Cabozantinib Does Not Improve SSE-FS in mRCC With Bone Metastases - Oncodaily

RADICAL Trial: Radium-223 Plus Cabozantinib Does Not Improve SSE-FS in mRCC With Bone Metastases  Oncodaily